BeiGene, Ltd. (BGNE) News

BeiGene, Ltd. (BGNE): $138.00

8.82 (+6.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BGNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 389

in industry

Filter BGNE News Items

BGNE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BGNE News Highlights

  • BGNE's 30 day story count now stands at 16.
  • Over the past 25 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • The most mentioned tickers in articles about BGNE are DRUG, SNDA and WM.

Latest BGNE News From Around the Web

Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

BeiGene''s Brukinsa Applications Under FDA, European Review For Leukemia

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd''s (NASDAQ: BGNE ) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its

Benzinga | February 22, 2022

BeiGene''s Brukinsa gets FDA review for expanded use in blood cancer subtype

The U.S. Food and Drug Administration ((FDA)) accepted BeiGene''s (BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic

Seeking Alpha | February 22, 2022

BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its first approval in the European Union (EU) for Waldenström's macroglobulinemia (WM), who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. Additionally, the FDA has als

Yahoo | February 22, 2022

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocyt

Yahoo | February 22, 2022

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass. and BEIJING, February 22, 2022--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

Yahoo | February 22, 2022

BeiGene''s Brukinsa for blood cancer subtype gets approval in Switzerland

BeiGene''s (BGNE) Brukinsa (zanubrutinib) was approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia ((WM)) who have received at least one prior line of…

Seeking Alpha | February 17, 2022

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 17, 2022--BeiGene announces approval for BRUKINSA (zanubrutinib) by Swissmedic for the treatment of adult patients with Waldenström’s Macroglobulinemia

Yahoo | February 17, 2022

BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference

CAMBRIDGE, Mass. & BEIJING, February 08, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET.

Yahoo | February 8, 2022

Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors

CAMBRIDGE, Mass. & BEIJING, February 01, 2022--BeiGene announces the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors.

Yahoo | February 1, 2022

BeiGene''s Brukinsa application accepted in China for chronic lymphocytic leukemia

BeiGene (BGNE) announces its supplemental new drug application (sNDA) for BTK inhibitor BRUKINSA (zanubrutinib) has accepted by China National Medical Products Administration

Seeking Alpha | January 28, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6888 seconds.